Stifel has revised its price target for Glaukos Corporation (GKOS, Financial), decreasing it from $175 to $140 while maintaining a Buy rating on the stock. This adjustment comes after a survey of 34 surgeons using Glaukos's iDose product revealed stagnant procedure volumes during the first quarter. The lack of growth in iDose procedures has tempered expectations for a strong first-quarter performance. Despite the revised outlook, Stifel continues to express confidence in the company’s potential, albeit with moderated optimism.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Glaukos Corp (GKOS, Financial) is $156.23 with a high estimate of $200.00 and a low estimate of $110.00. The average target implies an upside of 65.29% from the current price of $94.52. More detailed estimate data can be found on the Glaukos Corp (GKOS) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Glaukos Corp's (GKOS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Glaukos Corp (GKOS, Financial) in one year is $104.96, suggesting a upside of 11.05% from the current price of $94.52. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Glaukos Corp (GKOS) Summary page.
